CD274 and hepatocellular carcinoma: In recent years, immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) and targeted therapies (e.g., sorafenib, lenvatinib) have substantially changed the treatment landscape of advanced HCC [32].